Polycyclo Ring System Patents (Class 514/569)
-
Patent number: 8252839Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula.Type: GrantFiled: April 8, 2008Date of Patent: August 28, 2012Assignee: United Therapeutics CorporationInventors: Ken Phares, David Mottola
-
Patent number: 8252330Abstract: In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.Type: GrantFiled: January 4, 2010Date of Patent: August 28, 2012Assignee: McNEIL-PPC, Inc.Inventors: Satish Kamath, Michael Nichols
-
Publication number: 20120214869Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.Type: ApplicationFiled: April 30, 2012Publication date: August 23, 2012Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Thibaud BIADATTI, Jean-Marie Arlabosse
-
Patent number: 8246988Abstract: In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.Type: GrantFiled: January 4, 2010Date of Patent: August 21, 2012Assignee: McNeil-PPC, Inc.Inventors: Satish Kamath, Indukumar G. Shah, Michael Nichols, Dinesh Patel
-
Publication number: 20120202694Abstract: The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: August 9, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Patent number: 8236857Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: GrantFiled: March 19, 2012Date of Patent: August 7, 2012Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Patent number: 8236856Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: GrantFiled: March 19, 2012Date of Patent: August 7, 2012Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Publication number: 20120195932Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for to later addition of cargo moieties are also contemplated.Type: ApplicationFiled: January 25, 2010Publication date: August 2, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
-
Patent number: 8232253Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.Type: GrantFiled: December 17, 2007Date of Patent: July 31, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
-
Publication number: 20120190733Abstract: The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles or increasing one or more of: length, thickness, number, and density, of eyelash hair or eyebrow hair comprising applying to the skin of a patient a composition comprising an effective amount of an EP3 agonist or an EP4 agonist prodrug or a mixture thereof. Such compositions which are used in treating the skin or scalp of a human or non-human animal may comprise an effective amount of 3, 7 or 3 and 7 thia prostanoic acid. A mixture of 3,7-dithia PGE1 and 3,7-dithiaPGE1-isopropyl ester is preferred for this treatment.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Inventors: Jenny W. Wang, David F. Woodward
-
Publication number: 20120190662Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.Type: ApplicationFiled: April 3, 2012Publication date: July 26, 2012Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
-
Publication number: 20120189713Abstract: The invention relates to novel monomers of Formula (I) useful for preparation of phase-separated biocompatible polymers or polymer compositions. These polymers or polymer compositions may be bioresorbable and/or biodegradable and have desirable mechanical properties, such as fracture and/or fatigue toughness, which have not been a primary design criteria for such polymers previously. The polymers or polymer compositions are useful in a variety of medical applications, such as in the fabrication of medical devices. Therefore, methods for preparing these polymers or polymer compositions and medical devices are also encompassed by this disclosure.Type: ApplicationFiled: July 31, 2010Publication date: July 26, 2012Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Joachim B. Kohn, Durgadas Bolikal, Ramiro Rojas
-
Publication number: 20120184622Abstract: The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.Type: ApplicationFiled: August 5, 2010Publication date: July 19, 2012Applicant: SCIPHARM SaRLInventors: Michael Freissmuth, Xaver Koenig, Christina Gloeckel
-
Publication number: 20120177693Abstract: Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.Type: ApplicationFiled: September 24, 2009Publication date: July 12, 2012Inventors: David C. Cipolla, Igor Gonda, Babatunde Otulana, Richard Morishige, Paul R. Bruinenberg
-
Publication number: 20120177726Abstract: The present invention relates to medical use of liposomes, more particular the first medical use of sPLA2 hydrolysable liposomes. Such liposomes may be used for targeted delivery of therapeutic agents to cancerous tissue and in such embodiments; the therapeutic agents are typically small molecule antitumor agents. Other aspects of the inventions relates to methods of reducing the side effects of therapeutic agents, e.g. reducing nephrotoxicity, neurotoxicity and gastrointestinal toxicity of a therapeutic agent. Yet another aspect of the present invention relate to methods of prolonging the therapeutic effect of a therapeutic agent.Type: ApplicationFiled: September 16, 2010Publication date: July 12, 2012Applicant: Bio-Bedst ApSInventors: Morten Just Petersen, Fredrik Melander, Andres Falk Vikbjerg, Sune Allan Petersonm, Mognes Winkel Madsen
-
Publication number: 20120165410Abstract: The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: June 28, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Publication number: 20120164192Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120164193Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Patent number: 8207228Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: GrantFiled: October 4, 2005Date of Patent: June 26, 2012Assignee: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Cheri
-
Publication number: 20120156244Abstract: Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Publication number: 20120148634Abstract: The present invention relates to methods for producing particles of naproxen using dry milling processes as well as compositions comprising naproxen, medicaments produced using naproxen in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of naproxen administered by way of said medicaments.Type: ApplicationFiled: April 23, 2010Publication date: June 14, 2012Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Publication number: 20120148665Abstract: The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.Type: ApplicationFiled: June 24, 2009Publication date: June 14, 2012Applicant: STRATEGIC SCIENCE & TECHNOLOGIES, LLCInventor: Eric T. Fossel
-
Publication number: 20120149654Abstract: The present invention relates to the two main categories of humic substances, humic acids and fulvic acids and their use for hindering the propagation and/or contamination with prion infectivity both in agricultural and environmental systems.Type: ApplicationFiled: July 13, 2010Publication date: June 14, 2012Applicant: SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATIInventors: Giuseppe Antonio Legname, Liviana Leita, Paolo Sequi
-
Publication number: 20120149697Abstract: The present invention relates to the medical field, in particular to the use of natural organic polyanions, i.e. humic substances, HSs, in the treatment of neurodegenerative diseases, such as Prion disease, Alzheimer's and Parkinson's disease.Type: ApplicationFiled: July 13, 2010Publication date: June 14, 2012Applicant: SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATIInventors: Giuseppe Antonio Legname, Liviana Leita, Paolo Sequi
-
Publication number: 20120141545Abstract: A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit.Type: ApplicationFiled: April 4, 2011Publication date: June 7, 2012Inventors: Richard C. Fuisz, Joseph M. Fuisz
-
Publication number: 20120141554Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: January 4, 2012Publication date: June 7, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120141483Abstract: The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of psoriasis and/or Alzheimer's diseases using the same.Type: ApplicationFiled: June 3, 2010Publication date: June 7, 2012Inventor: Mary Katherine Delmedico
-
Publication number: 20120142707Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.Type: ApplicationFiled: June 2, 2011Publication date: June 7, 2012Inventors: Alicia Regueiro-Ren, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell, Sing-Yuen Sit, Jie Chen
-
Publication number: 20120135050Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: January 4, 2012Publication date: May 31, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20120136059Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.Type: ApplicationFiled: November 30, 2011Publication date: May 31, 2012Applicant: Galderma Research & DevelopmentInventors: Marie-line ABOU-CHACRA VERNET, Denis Gross, Christian Loesche, Michel Poncet
-
Patent number: 8188107Abstract: Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of N-[3 -(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and a-dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient a an oral dosage form comprising two analgesic compounds consisting of N-[3-(formylamino)-4-oxo-6 -phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and oxycodone and/or at least one a pharmaceutically acceptable salt thereof such that the two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.Type: GrantFiled: January 25, 2002Date of Patent: May 29, 2012Assignee: Purdue Pharma L.P.Inventors: Ronald M. Burch, Paul D. Goldenheim, Richard S. Sackler
-
Patent number: 8183290Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. In particular a 2:1 complex of naproxen sodium to propylene glycol is disclosed which is a crystalline solid. The complex is prepared by crystallization of a mixture of naproxen sodium and propylene glycol from diethyl ether. It is identifiable by its X-ray powder diffraction pattern described herein.Type: GrantFiled: July 20, 2010Date of Patent: May 22, 2012Assignee: McNeil-PPC, Inc.Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
-
Publication number: 20120122870Abstract: Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.Type: ApplicationFiled: May 10, 2010Publication date: May 17, 2012Applicants: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, APOGEE BIOTECHNOLOGY CORPORATIONInventors: Charles D. Smith, Zhi Zhong, Lynn W. Maines
-
Publication number: 20120122823Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.Type: ApplicationFiled: September 13, 2011Publication date: May 17, 2012Applicant: Bev-RX. Inc.Inventor: Kyle A. Reed
-
Publication number: 20120122987Abstract: Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation.Type: ApplicationFiled: July 14, 2010Publication date: May 17, 2012Applicants: Temple University of the Commonwealth System of Higher Education, Research Triangle Institute, Duke UniversityInventors: Mary E. Abood, Pingwei Zhao, Lawrence S. Barak, Herbert H. Seltzman
-
Publication number: 20120121711Abstract: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).Type: ApplicationFiled: July 30, 2010Publication date: May 17, 2012Applicant: XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD.Inventors: Renle Hu, Jiucheng Wang, Tao Chen, Hua Liang, Duohao Ding, Yaqi Jiao
-
Publication number: 20120114740Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: October 27, 2011Publication date: May 10, 2012Applicant: PACIRA PHARMACEUTICALS, INCInventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Publication number: 20120114754Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.Type: ApplicationFiled: November 8, 2011Publication date: May 10, 2012Inventors: Rajeev A. Jain, Stephen B. RUDDY, Kenneth Iain CUMMING, Maurice Joseph Anthony CLANCY, Janet Elizabeth CODD
-
Publication number: 20120107400Abstract: A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of time at pH prevalent in the intestinal region.Type: ApplicationFiled: March 5, 2010Publication date: May 3, 2012Inventors: Ramesh Muthusamy, Mohan Gopalkrishna Kulkarni
-
Publication number: 20120108551Abstract: The present invention relates to compositions that may alleviate symptoms of ocular stress, as well as methods of their production, use, and storage compositions. The compositions comprise at least one ocular epithelial cell associating group and at least one hydrophilic group. In one embodiment the at least one ocular epithelial cell associating group and at least one hydrophilic group are substituents on a conjugated polyaromatic core. The compositions may be used in ophthalmic compositions and ophthalmic devices.Type: ApplicationFiled: October 29, 2010Publication date: May 3, 2012Inventors: Frank F. Molock, JR., John C. Heaton
-
Publication number: 20120094956Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.Type: ApplicationFiled: December 12, 2011Publication date: April 19, 2012Inventor: Roshantha A. Chandraratna
-
Publication number: 20120093917Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical inhibitors of DNA repair proteins (Metnase) and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols.Type: ApplicationFiled: March 31, 2010Publication date: April 19, 2012Inventors: Robert Hromas, Andrei Leitao, Tudor I. Oprea, Larry A. Sklar, Elizabeth A. Williamson, Justin Wray
-
Publication number: 20120095048Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: February 19, 2010Publication date: April 19, 2012Applicants: REGION MIDT JYLLAND, AARHUS UNIVERSITETInventors: Henrik Amtoft Neubauer, Ove Kjaer Wiborg, Henrik Helligsø Jensen
-
Publication number: 20120088784Abstract: The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.Type: ApplicationFiled: November 4, 2011Publication date: April 12, 2012Inventors: Boulos Zacharie, Christopher Penney, Lyne Gagnon, Jean-François Bienvenu, Valérie Perron, Brigitte Grouix
-
Publication number: 20120070492Abstract: The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions.Type: ApplicationFiled: September 13, 2008Publication date: March 22, 2012Inventors: Rahul Dabre, Girish Kumar Jain, Cyril Estanove, François Pruvost, Roshanlal Sandal, Prashant Mandaogade, Premchand Nakhat
-
Publication number: 20120071550Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.Type: ApplicationFiled: July 18, 2011Publication date: March 22, 2012Applicant: LYCORED LTD.Inventors: Morris Zelkha, Rachel Levy, Esther Paran, Yoav Sharoni, Joseph Levy
-
Publication number: 20120064135Abstract: The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact with one another. The composition is designed to allow all ingredients to become available for skin contact or skin absorption when the fatty substance softens and/or melts as the composition is applied to the skin. The benzoyl peroxide may be pre-micronized to a particle distribution size of about d90 of 0.1 to 150 microns, preferably d90 of 10 to 15 microns.Type: ApplicationFiled: August 16, 2011Publication date: March 15, 2012Applicant: Norac PharmaInventors: Daniel Levin, Arthur Harms
-
Publication number: 20120065232Abstract: The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) ?-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of retinoid compounds in a composition by at least 3-fold.Type: ApplicationFiled: October 27, 2011Publication date: March 15, 2012Applicant: HALLSTAR INNOVATIONS CORP.Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
-
Publication number: 20120064136Abstract: The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising administering to the subject in need thereof a nanoemulsion composition.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Inventors: James R. Baker, JR., Susan M. Ciotti
-
Patent number: RE43372Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.Type: GrantFiled: June 5, 2009Date of Patent: May 8, 2012Assignee: Duke UniversityInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De